Current perspectives on the diagnosis and management of acute transverse myelitis

References

• Transverse Myelitis Consortium Working G. Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology. 2002;59(4):499.
   PubMed Web of Science ®Google Scholar
• Epidemiologists CoSaT. Revision to the standardized case definition, case classification, and public health reporting for acute flaccid myelitis. 2021 [Cited 2023 Jan 4]. Available from: https://www.cdc.gov/acute-flaccid-myelitis/hcp/case-definitions.html
   Google Scholar
• Abbatemarco JR, Galli JR, Sweeney ML, et al. Modern look at transverse myelitis and inflammatory myelopathy: epidemiology of the national veterans health administration population. Neurol Neuroimmunol Neuroinflamm. 2021;8(6):e1071.
   PubMedGoogle Scholar
• Zalewski NL, Flanagan EP, Keegan BM. Evaluation of idiopathic transverse myelitis revealing specific myelopathy diagnoses. Neurology. 2018;90(2):e96–e102.
   PubMed Web of Science ®Google Scholar
• Murphy OC, Barreras P, Villabona-Rueda A, et al. Identification of specific causes of myelopathy in a large cohort of patients initially diagnosed with transverse myelitis. J Neurol Sci. 2022; 442:120425.
   PubMedGoogle Scholar
• Barreras P, Fitzgerald KC, Mealy MA, et al. Clinical biomarkers differentiate myelitis from vascular and other causes of myelopathy. Neurology. 2018;90(1):e12–e21.
   PubMed Web of Science ®Google Scholar
• Jurynczyk M, Messina S, Woodhall MR, et al. Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain. 2017;140(12):3128–3138.
   PubMedGoogle Scholar
• McLaren N, Lopez A, Kidd S, et al. Characteristics of patients with acute flaccid myelitis, United States, 2015-2018. Emerg Infect Dis. 2020 Feb;26(2):212–219.
   PubMedGoogle Scholar
• Flanagan EP, McKeon A, Lennon VA, et al. Paraneoplastic isolated myelopathy. Neurology. 2011;76(24):2089.
   PubMedGoogle Scholar
• Kitley J, Leite MI, Küker W, et al. Longitudinally extensive transverse myelitis with and without aquaporin 4 antibodies. JAMA Neurol. 2013 Nov;70(11):1375–1381.
   PubMedGoogle Scholar
• Sabel CE, Pearson JF, Mason DF, et al. The latitude gradient for multiple sclerosis prevalence is established in the early life course. Brain. 2021 Aug 17;144(7):2038–2046.
   PubMedGoogle Scholar
• Langer-Gould AM, Gonzales EG, Smith JB, et al. Racial and ethnic disparities in multiple sclerosis prevalence. Neurology. 2022 May 3;98(18):e1818–e1827.
   PubMedGoogle Scholar
• Flanagan EP, Cabre P, Weinshenker BG, et al. Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum. Ann Neurol. 2016 May 01;79(5):775–783.
   PubMed Web of Science ®Google Scholar
• Hor JY, Asgari N, Nakashima I, et al. Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide [Review]. Front Neurol. 2020 June 26;11:501.
   PubMed Web of Science ®Google Scholar
• Cheong WL, Mohan D, Warren N, et al. Multiple sclerosis in the Asia Pacific region: a systematic review of a neglected neurological disease [Systematic Review]. Front Neurol. 2018 June 08;9:432.
   PubMed Web of Science ®Google Scholar
• Arkema EV, Cozier YC. Sarcoidosis epidemiology: recent estimates of incidence, prevalence and risk factors. Curr Opin Pulm Med. 2020;26(5):527–534.
   PubMed Web of Science ®Google Scholar
• Leonardo NM, McNeil J. Behcet’s disease: is there geographical variation? A review far from the silk road. Int J Rheumatol. 2015;2015:945262–945262.
   PubMedGoogle Scholar
• Brody IA, Wilkins RH. Lhermitte’s Sign. Arch Neurol. 1969;21(3):338–339.
   PubMedGoogle Scholar
• Babinski J, Dubois R. Douleurs à forme de décharge électrique consécutives aux traumatismes de la nuque. Presse Med. 1918;26:64.
   Google Scholar
• Syc-Mazurek SB, Montenegro M, Clarke MJ, et al. MRI with neck extension to diagnose cervical spondylotic myelopathy. Pract Neurol. 2022 Apr;22(2):162–163.
   PubMedGoogle Scholar
• Du Q, Shi Z, Chen H, et al. Mortality of neuromyelitis optica spectrum disorders in a Chinese population. Ann Clin Transl Neurol. 2021 Jul;8(7):1471–1479.
   PubMedGoogle Scholar
• Jarius S, Ruprecht K, Kleiter I, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation. 2016;13(1):280.
   PubMed Web of Science ®Google Scholar
• Cabre P, González-Quevedo A, Bonnan M, et al. Relapsing neuromyelitis optica: long term history and clinical predictors of death. J Neurol Neurosurg. 2009;80(10):1162–1164.
   PubMed Web of Science ®Google Scholar
• Dubey D, Pittock SJ, Krecke KN, et al. Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody. JAMA Neurol. 2019;76(3):301.
   PubMed Web of Science ®Google Scholar
• Flanagan EP, Kaufmann TJ, Krecke KN, et al. Discriminating long myelitis of neuromyelitis optica from sarcoidosis. Ann Neurol. 2016 Mar;79(3):437–447.
   PubMed Web of Science ®Google Scholar
• Flanagan EP, Weinshenker BG, Krecke KN, et al. Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders. JAMA Neurol. 2015;72(1):81–87.
   PubMed Web of Science ®Google Scholar
• Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177.
   PubMed Web of Science ®Google Scholar
• Chen JJ, Flanagan EP, Bhatti MT, et al. Details and outcomes of a large cohort of MOG-IgG associated optic neuritis. Mult Scler Relat Disord. 2022 December 01;68:104237.
   PubMedGoogle Scholar
• Flanagan EP, Hinson SR, Lennon VA, et al. Glial fibrillary acidic protein immunoglobulin G as biomarker of autoimmune astrocytopathy: analysis of 102 patients. Ann Neurol. 2017;81(2):298–309.
   PubMed Web of Science ®Google Scholar
• Sechi E, Morris PP, McKeon A, et al. Glial fibrillary acidic protein IgG related myelitis: characterisation and comparison with aquaporin-4-IgG myelitis. J Neurol Neurosurg. 2019;90(4):488.
   PubMed Web of Science ®Google Scholar
• Dubey D, Hinson SR, Jolliffe EA, et al. Autoimmune GFAP astrocytopathy: prospective evaluation of 90 patients in 1 year. J Neuroimmunol. 2018 August 15;321:157–163.
   PubMed Web of Science ®Google Scholar
• Gravier-Dumonceau A, Ameli R, Rogemond V, et al. Glial fibrillary acidic protein autoimmunity: a French cohort study. Neurology. 2022;98(6):e653–e668.
   PubMedGoogle Scholar
• Pittock SJ, Yoshikawa H, Ahlskog JE, et al. Glutamic acid decarboxylase autoimmunity with brainstem, extrapyramidal, and spinal cord dysfunction. Mayo Clin Proc. 2006;81(9):1207–1214.
   PubMedGoogle Scholar
• McKeon A, Robinson MT, McEvoy KM, et al. Stiff-man syndrome and variants: clinical course, treatments, and outcomes. Arch Neurol. 2012;69(2):230–238.
   PubMedGoogle Scholar
• Hutchinson M, Waters P, McHugh J, et al. Progressive encephalomyelitis, rigidity, and myoclonus: a novel glycine receptor antibody. Neurology. 2008 Oct 14;71(16):1291–1292.
   PubMed Web of Science ®Google Scholar
• Chamard L, Magnin E, Berger E, et al. Stiff leg syndrome and myelitis with anti-amphiphysin antibodies: a common physiopathology? Eur Neurol. 2011;66(5):253–255.
   PubMedGoogle Scholar
• Fritz D, van de Beek D, Brouwer MC. Clinical features, treatment and outcome in neurosarcoidosis: systematic review and meta-analysis. BMC Neurol. 2016;16(1):220–220.
   PubMedGoogle Scholar
• Toledano M. Infectious myelopathies. Continuum (Minneap Minn). 2021 Feb 1; 27(1):93–120.
   PubMedGoogle Scholar
• Rinaldi S, Davies A, Fehmi J, et al. Overlapping central and peripheral nervous system syndromes in MOG antibody-associated disorders. Neurol Neuroimmunol Neuroinflamm. 2021 Jan;8(1):e924.
   PubMedGoogle Scholar
• Vickers ML, Seidl B, Bigby K, et al. Inflammatory myeloradiculitis secondary to pembrolizumab: a case report and literature review. Case Rep Oncol Med. 2020;2020:8819296.
   PubMedGoogle Scholar
• Shah S, Vazquez Do Campo R, Kumar N, et al. Paraneoplastic Myeloneuropathies. Neurology. 2021;96(4):e632.
   PubMedGoogle Scholar
• Zalewski NL, Rabinstein AA, Krecke KN, et al. Characteristics of spontaneous spinal cord infarction and proposed diagnostic criteria. JAMA Neurol. 2019 Jan 1;76(1):56–63.
   PubMed Web of Science ®Google Scholar
• Andrade P, Figueiredo C, Carvalho C, et al. Transverse myelitis and acute HIV infection: a case report. BMC Infect Dis. 2014;14:149–149.
   PubMedGoogle Scholar
• Bahr N, Boulware DR, Marais S, et al. Central nervous system immune reconstitution inflammatory syndrome. Curr Infect Dis Rep. 2013;15(6):583–593.
   PubMed Web of Science ®Google Scholar
• Clark BM, Krueger RG, Price P, et al. Compartmentalization of the immune response in varicella zoster virus immune restoration disease causing transverse myelitis. Aids. 2004 May 21;18(8):1218–1221.
   PubMedGoogle Scholar
• Koga M, Takahashi T, Kawai M, et al. A serological analysis of viral and bacterial infections associated with neuromyelitis optica. J Neurol Sci. 2011 Jan 15;300(1–2):19–22.
   PubMed Web of Science ®Google Scholar
• Gilden D, Cohrs RJ, Mahalingam R, et al. Varicella zoster virus vasculopathies: diverse clinical manifestations, laboratory features, pathogenesis, and treatment. Lancet Neurol. 2009 Aug 8;8:731–740.
   PubMed Web of Science ®Google Scholar
• Ng KS, Abdul Halim S. Anterior spinal cord syndrome as a rare complication of acute bacterial meningitis in an adult. BMJ Case Rep. 2018 Oct 24;2018:bcr2018226082.
   PubMedGoogle Scholar
• Román GC, Gracia F, Torres A, et al. Acute Transverse Myelitis (ATM): clinicalReview of 43 patients with COVID-19-Associated ATM and 3 post-vaccination ATM serious adverse events with the ChAdOx1 nCoV-19 vaccine (AZD1222). Front Immunol. 2021;12:653786.
   PubMed Web of Science ®Google Scholar
• Sotoca J, Rodríguez-Álvarez Y. COVID-19-associated acute necrotizing myelitis. Neurol Neuroimmunol Neuroinflamm. 2020 Sep;7(5):e803.
   PubMedGoogle Scholar
• Mondal R, Deb S, Shome G, et al. COVID-19 and emerging spinal cord complications: a systematic review. Mult Scler Relat Disord. 2021 Jun;51:102917.
   PubMedGoogle Scholar
• Anamnart C, Tisavipat N, Owattanapanich W, et al. Newly diagnosed neuromyelitis optica spectrum disorders following vaccination: case report and systematic review. Mult Scler Relat Disord. 2022 February 01;58:103414.
   PubMedGoogle Scholar
• Ismail II, Salama S. A systematic review of cases of CNS demyelination following COVID-19 vaccination. J Neuroimmunol. 2022 Jan 15;362:577765.
   PubMed Web of Science ®Google Scholar
• Francis AG, Elhadd K, Camera V, et al. Acute inflammatory diseases of the central nervous system after SARS-CoV-2 vaccination. Neurol Neuroimmunol Neuroinflamm. 2022;10(1):e200063.
   PubMedGoogle Scholar
• Iorio R, Damato V, Evoli A, et al. Clinical and immunological characteristics of the spectrum of GFAP autoimmunity: a case series of 22 patients. J Neurol Neurosurg Psychiatry. 2018 Feb;89(2):138–146.
   PubMed Web of Science ®Google Scholar
• Asnafi S, Morris PP, Sechi E, et al. The frequency of longitudinally extensive transverse myelitis in MS: a population-based study. Mult Scler Relat Disord. 2020 January 01;37:101487.
   PubMedGoogle Scholar
• Nolte JYC, Ten Dam L, van de Beek D, et al. Clinical characteristics and outcome of neurosarcoidosis-associated myelitis: a retrospective cohort study and review of the literature. Eur J Neurol. 2022;29(6):1763–1770.
   PubMedGoogle Scholar
• Kunchok A, Flanagan EP, Snyder M, et al. Coexisting systemic and organ-specific autoimmunity in MOG-IgG1-associated disorders versus AQP4-IgG+ NMOSD. Mult Scler. 2021 Apr;27(4):630–635.
   PubMedGoogle Scholar
• Guerra H, Pittock SJ, Moder KG, et al. Frequency of Aquaporin-4 Immunoglobulin G in longitudinally extensive transverse myelitis with antiphospholipid antibodies. Mayo Clin Proc. 2018 Sep;93(9):1299–1304.
   PubMedGoogle Scholar
• Muñoz-Lopetegi A, de Bruijn MAAM, Boukhrissi S, et al. Neurologic syndromes related to anti-GAD65. Neurol Neuroimmunol Neuroinflammat. 2020;7(3):e696.
   PubMedGoogle Scholar
• Budhram A, Sechi E, Flanagan EP, et al. Clinical spectrum of high-titre GAD65 antibodies. J Neurol Neurosurg. 2021;92(6):645.
   Google Scholar
• Marini A, Bernardini A, Gigli GL, et al. Neurologic adverse events of immune checkpoint inhibitors: a systematic review. Neurology. 2021 Apr 20;96(16):754–766.
   PubMed Web of Science ®Google Scholar
• Hutto SK, Rice DR, Mateen FJ. CNS demyelination with TNFα inhibitor exposure: a retrospective cohort study. J Neuroimmunol. 2021 July 15;356:577587.
   PubMed Web of Science ®Google Scholar
• Redenbaugh V, Flanagan E, Floris V, et al. MOG-IgG associated disease is uncommon during treatment with TNF inhibitors (P9-1.005). Neurology. 2022;98(18Supplement):1792.
   Google Scholar
• Lommers E, Depierreux F, Hansen I, et al. NMOSD with anti-MOG antibodies following anti-TNFα therapy: a case report. Mult Scler Relat Disord. 2018 November 01;26:37–39.
   PubMedGoogle Scholar
• Kunchok A, Aksamit AJ Jr, Davis JM III, et al. Association between tumor necrosis factor inhibitor exposure and inflammatory central nervous system events. JAMA Neurol. 2020;77(8):937–946.
   PubMedGoogle Scholar
• Kumar N, Abboud H. Iatrogenic CNS demyelination in the era of modern biologics. Mult Scler J. 2019;25(8):1079–1085.
   PubMed Web of Science ®Google Scholar
• Richter RW, Rosenberg RN. Transverse myelitis associated with heroin addiction. JAMA. 1968;206(6):1255–1257.
   PubMedGoogle Scholar
• Mustafa R, Passe TJ, Lopez-Chiriboga AS, et al. Utility of MRI enhancement pattern in myelopathies with longitudinally extensive T2 lesions. Neurol Clin Pract. 2021;11(5):e601.
   PubMedGoogle Scholar
• Kim HJ, Paul F, Lana-Peixoto MA, et al. MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology. 2015;84(11):1165–1173.
   PubMed Web of Science ®Google Scholar
• Klawiter EC, Benzinger T, Roy A, et al. Spinal cord ring enhancement in multiple sclerosis. Arch Neurol. 2010 Nov;67(11):1395–1398.
   PubMedGoogle Scholar
• Zalewski NL, Morris PP, Weinshenker BG, et al. Ring-enhancing spinal cord lesions in neuromyelitis optica spectrum disorders. J Neurol Neurosurg Psychiatry. 2017 Mar;88(3):218–225.
   PubMedGoogle Scholar
• Poullet Z, Pique J, Maarouf A, et al. Pure relapsing short myelitis: part of the multiple sclerosis spectrum or new entity? Neurol Neuroimmunol Neuroinflamm. 2022 Jul;9(4):e1167.
   PubMedGoogle Scholar
• Schee JP, Viswanathan S. Pure spinal multiple sclerosis: a possible novel entity within the multiple sclerosis disease spectrum. Mult Scler. 2019 Jul;25(8):1189–1195.
   PubMedGoogle Scholar
• Sechi E, Krecke KN, Messina SA, et al. Comparison of MRI lesion evolution in different central nervous system demyelinating disorders. Neurology. 2021 Sep 14;97(11):e1097–e1109.
   PubMedGoogle Scholar
• Ciron J, Cobo-Calvo A, Audoin B, et al. Frequency and characteristics of short versus longitudinally extensive myelitis in adults with MOG antibodies: a retrospective multicentric study. Mult Scler. 2020 Jul;26(8):936–944.
   PubMedGoogle Scholar
• Webb L, Cacciaguerra L, Chen J, et al. Spinal central canal dilation in MOG antibody-associated disease versus other CNS demyelinating disorders. Neurology. 2022;99(23 Supplement 2):S21–S22.
   Google Scholar
• Mariano R, Messina S, Kumar K, et al. Comparison of clinical outcomes of transverse myelitis among adults with myelin oligodendrocyte glycoprotein antibody vs aquaporin-4 antibody disease. JAMA Network Open. 2019;2(10):e1912732.
   PubMedGoogle Scholar
• Soni N, Bathla G, Pillenahalli Maheshwarappa R. Imaging findings in spinal sarcoidosis: a report of 18 cases and review of the current literature. Neuroradiol J. 2019 Feb;32(1):17–28.
   PubMedGoogle Scholar
• Durel CA, Marignier R, Maucort-Boulch D, et al. Clinical features and prognostic factors of spinal cord sarcoidosis: a multicenter observational study of 20 BIOPSY-PROVEN patients. J Neurol. 2016 May;263(5):981–990.
   PubMed Web of Science ®Google Scholar
• Murphy OC, Salazar-Camelo A, Jimenez JA, et al. Clinical and MRI phenotypes of sarcoidosis-associated myelopathy. Neurol Neuroimmunol Neuroinflamm. 2020 Jul 2;7(4):e722.
   PubMedGoogle Scholar
• Nesbit GM, Miller GM, Baker HL Jr., et al. Spinal cord sarcoidosis: a new finding at MR imaging with Gd-DTPA enhancement. Radiology. 1989 Dec;173(3):839–843.
   PubMedGoogle Scholar
• Zalewski NL, Krecke KN, Weinshenker BG, et al. Central canal enhancement and the trident sign in spinal cord sarcoidosis. Neurology. 2016;87(7):743–744.
   PubMedGoogle Scholar
• Boban J, Thurnher MM. Ventral-subpial enhancement in spinal cord sarcoidosis: a braid-like sign. Neurology. 2019 Jan;92(5):236–238.
   Google Scholar
• McKeon A, Tracy JA. GAD65 neurological autoimmunity. Muscle Nerve. 2017;56(1):15–27.
   PubMedGoogle Scholar
• Delalande S, de Seze J, Fauchais A-L, et al. Neurologic manifestations in primary sjögren syndrome: a study of 82 patients. Medicine (Baltimore). 2004;83(5):280–291.
   PubMed Web of Science ®Google Scholar
• Schulz SW, Shenin M, Mehta A, et al. Initial presentation of acute transverse myelitis in systemic lupus erythematosus: demographics, diagnosis, management and comparison to idiopathic cases. Rheumatol Int. 2012 Sep;32(9):2623–2627.
   PubMedGoogle Scholar
• Jarius S, Jacobi C, de Seze J, et al. Frequency and syndrome specificity of antibodies to aquaporin-4 in neurological patients with rheumatic disorders. Mult Scler. 2011 Sep;17(9):1067–1073.
   PubMedGoogle Scholar
• Asgari N, Jarius S, Laustrup H, et al. Aquaporin-4-autoimmunity in patients with systemic lupus erythematosus: a predominantly population-based study. Mult Scler. 2018 Mar;24(3):331–339.
   PubMedGoogle Scholar
• Uygunoglu U, Zeydan B, Ozguler Y, et al. Myelopathy in behçet’s disease: the bagel sign. Ann Neurol. 2017 Aug;82(2):288–298.
   PubMed Web of Science ®Google Scholar
• Lee HS, Kim Do Y, Shin HY, et al. Spinal cord involvement in Behçet’s disease. Mult Scler. 2016 Jun;22(7):960–963.
   PubMedGoogle Scholar
• Sechi E, Krecke KN, Pittock SJ, et al. Frequency and characteristics of MRI-negative myelitis associated with MOG autoantibodies. Mult Scler. 2021;27(2):303–308.
   PubMedGoogle Scholar
• Majed M, Fryer JP, McKeon A, et al. Clinical utility of testing AQP4-IgG in CSF: guidance for physicians. Neurol Neuroimmunol Neuroinflamm. 2016;3(3):e231–e231.
   PubMed Web of Science ®Google Scholar
• Waters P, Reindl M, Saiz A, et al. Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. J Neurol Neurosurg. 2016;87(9):1005.
   PubMed Web of Science ®Google Scholar
• Redenbaugh V, Montalvo M, Sechi E, et al. Diagnostic value of aquaporin-4-IgG live cell based assay in neuromyelitis optica spectrum disorders. Mult Scler J Exp Transl Clin. 2021;7(4):20552173211052656.
   Google Scholar
• Waters PJ, Komorowski L, Woodhall M, et al. A multicenter comparison of MOG-IgG cell-based assays. Neurology. 2019;92(11):e1250–e1255.
   PubMed Web of Science ®Google Scholar
• Williams JP, Abbatemarco JR, Galli JJ, et al. Aquaporin-4 autoantibody detection by ELISA: a retrospective characterization of a commonly used assay. Mult Scler Int. 2021;2021:8692328.
   PubMedGoogle Scholar
• Reindl M, Schanda K, Woodhall M, et al. International multicenter examination of MOG antibody assays. Neurol Neuroimmunol Neuroinflammat. 2020;7(2):e674.
   PubMedGoogle Scholar
• Sechi E, Buciuc M, Pittock SJ, et al. Positive predictive value of myelin oligodendrocyte glycoprotein autoantibody testing. JAMA Neurol. 2021 Jun 1;78(6):741–746.
   PubMed Web of Science ®Google Scholar
• Banwell B, Bennett JL, Marignier R, et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD Panel proposed criteria. Lancet Neurol. 2023 Jan 24;22(3):268–282.
   PubMedGoogle Scholar
• Graus F, Vogrig A, Muñiz-Castrillo S, et al. Updated diagnostic criteria for paraneoplastic neurologic syndromes. Neurol Neuroimmunol Neuroinflammat. 2021;8(4):e1014.
   PubMed Web of Science ®Google Scholar
• Ruiz-García R, Martínez-Hernández E, Saiz A, et al. The diagnostic value of onconeural antibodies depends on how they are tested. Front Immunol. 2020;11:1482.
   PubMedGoogle Scholar
• Pittock SJ, Kryzer TJ, Lennon VA. Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol. 2004;56(5):715–719.
   PubMedGoogle Scholar
• Liu Z, Jiao L, Qiu Z, et al. Clinical characteristics of patients with paraneoplastic myelopathy. J Neuroimmunol. 2019 May 15;330:136–142.
   PubMedGoogle Scholar
• McKeon A, Pittock SJ, Lennon VA. CSF complements serum for evaluating paraneoplastic antibodies and NMO-IgG. Neurology. 2011;76(12):1108–1110.
   PubMed Web of Science ®Google Scholar
• Graus F, Saiz A, Dalmau J. GAD antibodies in neurological disorders — insights and challenges. Nat Rev Neurol. 2020 July 01;16(7):353–365.
   PubMedGoogle Scholar
• Dalakas MC, Li M, Fujii M, et al. Stiff person syndrome: quantification, specificity, and intrathecal synthesis of GAD65 antibodies. Neurology. 2001 Sep 11;57(5):780–784.
   PubMedGoogle Scholar
• Flanagan EP, Geschwind MD, Lopez-Chiriboga AS, et al. Autoimmune encephalitis misdiagnosis in adults. JAMA Neurol. 2023 Jan 1;80(1):30–39.
   PubMedGoogle Scholar
• Valencia-Sanchez C, Knight AM, Hammami MB, et al. Characterisation of TRIM46 autoantibody-associated paraneoplastic neurological syndrome. J Neurol Neurosurg Psychiatry. 2022 Feb;93(2):196–200.
   PubMedGoogle Scholar
• Jarius S, Ruprecht K, Wildemann B, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation. 2012 Jan 19;9(1):14.
   PubMedGoogle Scholar
• Crouser ED, Maier LA, Wilson KC, et al. Diagnosis and detection of sarcoidosis. an official american thoracic society clinical practice guideline. Am J Respir Crit Care Med. 2020 Apr 15;201(8):e26–e51.
   PubMed Web of Science ®Google Scholar
• Ungprasert P, Carmona EM, Crowson CS, et al. Diagnostic utility of angiotensin-converting enzyme in sarcoidosis: a population-based study. Lung. 2016 Feb;194(1):91–95.
   PubMed Web of Science ®Google Scholar
• Andersson M, Alvarez-Cermeño J, Bernardi G, et al. Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. J Neurol Neurosurg Psychiatry. 1994 Aug;57(8):897–902.
   PubMed Web of Science ®Google Scholar
• Akaishi T, Takahashi T, Misu T, et al. Difference in the source of anti-AQP4-IgG and Anti-MOG-IgG antibodies in CSF in patients with neuromyelitis optica spectrum disorder. Neurology. 2021;97(1):e1.
   PubMed Web of Science ®Google Scholar
• Kwon YN, Kim B, Kim J-S, et al. Myelin oligodendrocyte glycoprotein-immunoglobulin G in the CSF: clinical implication of testing and association with disability. Neurol Neuroimmunol Neuroinflamm. 2022 Jan;9(1):e1095.
   PubMedGoogle Scholar
• Jarius S, Ruprecht K, Kleiter I, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. J Neuroinflammation. 2016 Sep 26;13(1):279.
   PubMedGoogle Scholar
• Mariotto S, Gajofatto A, Batzu L, et al. Relevance of antibodies to myelin oligodendrocyte glycoprotein in CSF of seronegative cases. Neurology. 2019 Nov 12;93(20):e1867–e1872.
   PubMed Web of Science ®Google Scholar
• Pace S, Orrell M, Woodhall M, et al. Frequency of MOG-IgG in cerebrospinal fluid versus serum. J Neurol Neurosurg. 2022;93(3):334–335.
   Google Scholar
• Van Haren K, Ayscue P, Waubant E, et al. Acute flaccid myelitis of unknown etiology in California, 2012-2015. Jama. 2015 Dec 22-29;314(24):2663–2671.
   PubMed Web of Science ®Google Scholar
• Messacar K, Schreiner TL, Maloney JA, et al. A cluster of acute flaccid paralysis and cranial nerve dysfunction temporally associated with an outbreak of enterovirus D68 in children in Colorado, USA. Lancet. 2015 Apr 25;385(9978):1662–1671.
   PubMed Web of Science ®Google Scholar
• Messacar K, Schreiner TL, Van Haren K, et al. Acute flaccid myelitis: a clinical review of US cases 2012–2015. Ann Neurol. 2016 Sep;80(3):326–338.
   PubMed Web of Science ®Google Scholar
• Chong PF, Kira R, Mori H, et al. Clinical features of acute flaccid myelitis temporally associated with an enterovirus d68 outbreak: results of a nationwide survey of acute flaccid paralysis in Japan, August–December 2015. Clin Infect Dis. 2018 Feb 10;66(5):653–664.
   PubMed Web of Science ®Google Scholar
• Kidd S, Yee E, English R, et al. National surveillance for acute flaccid myelitis — United States, 2018–2020. MMWR Morb Mortal Wkly Rep. 2021;70(44):1534–1538.
   PubMedGoogle Scholar
• Knoester M, Helfferich J, Poelman R, et al. Twenty-nine cases of enterovirus-d68–associated acute flaccid myelitis in Europe 2016. Pediatr Infect Dis J. 2019 Jan;38(1):16–21.
   PubMedGoogle Scholar
• Carballo CM, Erro MG, Sordelli N, et al. Acute flaccid myelitis associated with enterovirus D68 in children, Argentina, 2016. Emerg Infect Dis. 2019;25(3):573–576.
   PubMedGoogle Scholar
• Messacar K, Spence-Davizon E, Osborne C, et al. Clinical characteristics of enterovirus A71 neurological disease during an outbreak in children in Colorado, USA, in 2018: an observational cohort study. Lancet Infect Dis. 2020 Feb;20(2):230–239.
   PubMedGoogle Scholar
• Lopalco PL. Wild and vaccine-derived poliovirus circulation, and implications for polio eradication. Epidemiol Infect. 2017 Feb;145(3):413–419.
   PubMed Web of Science ®Google Scholar
• Estivariz CF, Kovacs SD, Mach O. Review of use of inactivated poliovirus vaccine in campaigns to control type 2 circulating vaccine derived poliovirus (cVDPV) outbreaks. Vaccine. 2022 March 29. doi: 10.1016/j.vaccine.2022.03.027.
   PubMedGoogle Scholar
• Flanagan EP, Krecke KN, Marsh RW, et al. Specific pattern of gadolinium enhancement in spondylotic myelopathy. Ann Neurol. 2014 Jul;76(1):54–65.
   PubMedGoogle Scholar
• Minami S, Sagoh T, Nishimura K, et al. Spinal arteriovenous malformation: MR imaging. Radiology. 1988;169(1):109–115.
   PubMedGoogle Scholar
• Zalewski NL, Rabinstein AA, Brinjikji W, et al. Unique gadolinium enhancement pattern in spinal dural arteriovenous fistulas. JAMA Neurol. 2018 Dec 1;75(12):1542–1545.
   PubMedGoogle Scholar
• Terwey B, Becker H, Thron AK, et al. Gadolinium-DTPA enhanced MR imaging of spinal dural arteriovenous fistulas. J Comput Assist Tomogr. 1989;13(1):30–37.
   PubMedGoogle Scholar
• Brinjikji W, Colombo E, Cloft HJ, et al. Clinical and imaging characteristics of spinal dural arteriovenous fistulas and spinal epidural arteriovenous fistulas. Neurosurgery. 2021 Feb 16;88(3):666–673.
   PubMedGoogle Scholar
• Nasr DM, Brinjikji W, Rabinstein AA, et al. Clinical outcomes following corticosteroid administration in patients with delayed diagnosis of spinal arteriovenous fistulas. J Neurointerv Surg. 2017 Jun;9(6):607–610.
   PubMedGoogle Scholar
• Zalewski NL. Vascular Myelopathies. Continuum (Minneap Minn). 2021 Feb 1;27(1):30–61.
   PubMedGoogle Scholar
• Goodman BP. Metabolic and toxic causes of myelopathy. Continuum (Minneap Minn). 2015 Feb;21(1Spinal Cord Disorders):84–99.
   PubMedGoogle Scholar
• Gosavi T, Diong CP, Lim SH. Methotrexate-induced myelopathy mimicking subacute combined degeneration of the spinal cord. J Clin Neurosci. 2013 Jul;20(7):1025–1026.
   PubMedGoogle Scholar
• Rykken JB, Diehn FE, Hunt CH, et al. Rim and flame signs: postgadolinium MRI findings specific for non-CNS intramedullary spinal cord metastases. AJNR Am J Neuroradiol. 2013;34(4):908–915.
   PubMedGoogle Scholar
• Madhavan AA, Diehn FE, Rykken JB, et al. The central dot sign: a specific post-gadolinium enhancement feature of intramedullary spinal cord metastases. Clin Neuroradiol. 2021 Jun;31(2):383–390.
   PubMedGoogle Scholar
• Rykken JB, Diehn FE, Hunt CH, et al. Intramedullary spinal cord metastases: MRI and relevant clinical features from a 13-year institutional case series. AJNR Am J Neuroradiol. 2013 Oct;34(10):2043–2049.
   PubMedGoogle Scholar
• Flanagan EP, Neill BP, Porter AB, et al. Primary intramedullary spinal cord lymphoma. Neurology. 2011;77(8):784.
   PubMedGoogle Scholar
• Flanagan EP, O’Neill BP, Habermann TM, et al. Secondary intramedullary spinal cord non-Hodgkin’s lymphoma. J Neurooncol. 2012 May;107(3):575–580.
   PubMedGoogle Scholar
• Flanagan EP, Hunt CH, Lowe V, et al. [(18)F]-fluorodeoxyglucose-positron emission tomography in patients with active myelopathy. Mayo Clin Proc. 2013 Nov;88(11):1204–1212.
   PubMedGoogle Scholar
• Ptaszynski AE, Hooten WM, Huntoon MA. The incidence of spontaneous epidural abscess in olmsted county from 1990 through 2000: a rare cause of spinal pain. Pain Med. 2007;8(4):338–343.
   PubMedGoogle Scholar
• O’Keeffe DT, Mikhail MA, Lanzino G, et al. Corticosteroid-induced paraplegia—A diagnostic clue for spinal dural arterial venous fistula. JAMA Neurol. 2015;72(7):833–834.
   PubMedGoogle Scholar
• Kessler RA, Mealy MA, Levy M. Early indicators of relapses vs pseudorelapses in neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm. 2016;3(5):e269–e269.
   PubMed Web of Science ®Google Scholar
• Morrow SA, Stoian CA, Dmitrovic J, et al. The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis. Neurology. 2004 Sep 28;63(6):1079–1080.
   PubMed Web of Science ®Google Scholar
• Le Page E, Veillard D, Laplaud DA, et al. Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial. Lancet. 2015;386(9997):974–981.
   PubMedGoogle Scholar
• Demuth S, Guillaume M, Bourre B, et al. Treatment regimens for neuromyelitis optica spectrum disorder attacks: a retrospective cohort study. J Neuroinflammation. 2022 March 02;19(1):62.
   PubMedGoogle Scholar
• Banerjee A, Ng J, Coleman J, et al. Outcomes from acute attacks of neuromyelitis optica spectrum disorder correlate with severity of attack, age and delay to treatment. Mult Scler Relat Disord. 2019;28:60–63.
   PubMed Web of Science ®Google Scholar
• Akaishi T, Takahashi T, Misu T, et al. Progressive patterns of neurological disability in multiple sclerosis and neuromyelitis optica spectrum disorders. Sci Rep. 2020;10(1):13890.
   PubMed Web of Science ®Google Scholar
• Sechi E, Cacciaguerra L, Chen JJ, et al. Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): a review of clinical and MRI features, diagnosis, and management [Review]. Front Neurol. 2022 June 17;13:885218.
   PubMedGoogle Scholar
• Petrou P, Kassis I, Levin N, et al. Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis. Brain. 2020 Dec 1;143(12):3574–3588.
   PubMed Web of Science ®Google Scholar
• Boffa G, Massacesi L, Inglese M, et al. Long-term clinical outcomes of hematopoietic stem cell transplantation in multiple sclerosis. Neurology. 2021 Feb;20(8):e1215–e1226.
   Google Scholar
• Burt RK, Balabanov R, Burman J, et al. Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis: a randomized clinical trial. JAMA. 2019;321(2):165–174.
   PubMed Web of Science ®Google Scholar
• Chalmer TA, Baggesen LM, Nørgaard M, et al. Early versus later treatment start in multiple sclerosis: a register-based cohort study. Eur J Neurol. 2018 Oct;25(10):1262–e110.
   PubMedGoogle Scholar
• Brown JWL, Coles A, Horakova D, et al. Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. Jama. 2019 Jan 15;321(2):175–187.
   PubMed Web of Science ®Google Scholar
• Faer S, Plemel JR, Gold R, et al. Progressive multiple sclerosis: from pathophysiology to therapeutic strategies. Nat Rev Drug Discov. 2019 December 01;18(12):905–922.
   PubMed Web of Science ®Google Scholar
• Cross A, Riley C. Treatment of multiple sclerosis. Continuum (Minneap Minn). 2022 Aug 1; 28(4):1025–1051.
   PubMedGoogle Scholar
• McLaughlin L, Clarke L, Khalilidehkordi E, et al. Vitamin D for the treatment of multiple sclerosis: a meta-analysis. J Neurol. 2018 Dec;265(12):2893–2905.
   PubMed Web of Science ®Google Scholar
• Kleiter I, Gahlen A, Borisow N, et al. Neuromyelitis optica: evaluation of 871 attacks and 1,153 treatment courses. Ann Neurol. 2016;79(2):206–216.
   PubMed Web of Science ®Google Scholar
• Weinshenker BG, O’Brien PC, Petterson TM, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol. 1999;46(6):878–886.
   PubMed Web of Science ®Google Scholar
• Noland DK, Greenberg BM. Safety and efficacy of plasma exchange in pediatric transverse myelitis. Neurol Clin Pract. 2018;8(4):327–330.
   PubMedGoogle Scholar
• Songthammawat T, Srisupa - Olan T, Siritho S, et al. A pilot study comparing treatments for severe attacks of neuromyelitis optica spectrum disorders: intravenous methylprednisolone (IVMP) with add-on plasma exchange (PLEX) versus simultaneous ivmp and PLEX. Mult Scler Relat Disord. 2020 February 01;38:101506.
   PubMed Web of Science ®Google Scholar
• Bonnan M, Valentino R, Olindo S, et al. Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder. Mult Scler J. 2009;15(4):487–492.
   PubMed Web of Science ®Google Scholar
• Lim Y-M, Pyun SY, Kang B-H, et al. Factors associated with the effectiveness of plasma exchange for the treatment of NMO-IgG-positive neuromyelitis optica spectrum disorders. Mult Scler J. 2013;19(9):1216–1218.
   PubMedGoogle Scholar
• Czock D, Keller F, Rasche FM, et al. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet. 2005 January 01;44(1):61–98.
   PubMed Web of Science ®Google Scholar
• Elsone L, Panicker J, Mutch K, et al. Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients. Mult Scler J. 2014;20(4):501–504.
   PubMed Web of Science ®Google Scholar
• Li X, Tian D-C, Fan M, et al. Intravenous immunoglobulin for acute attacks in neuromyelitis optica spectrum disorders (NMOSD). Mult Scler Relat Disord. 2020 September 01;44:102325.
   PubMed Web of Science ®Google Scholar
• Lin J, Xue B, Zhu R, et al. Intravenous immunoglobulin as the rescue treatment in NMOSD patients. Neurol Sci. 2021 September 01;42(9):3857–3863.
   PubMedGoogle Scholar
• Pan J, Zhu R, Lin J, et al. Incidence and risk factors for venous thromboembolism during an acute attack in patients with neuromyelitis optica spectrum disorders. Mult Scler Relat Disord. 2022 February 01;58:103513.
   PubMedGoogle Scholar
• Guo Y, Tian X, Wang X, et al. Adverse effects of immunoglobulin therapy. Front Immunol. 2018;9:1299–1299.
   PubMed Web of Science ®Google Scholar
• Poupart J, Giovannelli J, Deschamps R, et al. Evaluation of efficacy and tolerability of first-line therapies in NMOSD. Neurology. 2020;94(15):e1645.
   PubMedGoogle Scholar
• Azzopardi L, Cox AL, McCarthy CL, et al. Alemtuzumab use in neuromyelitis optica spectrum disorders: a brief case series. J Neurol. 2016 Jan;263(1):25–29.
   PubMed Web of Science ®Google Scholar
• Min JH, Kim BJ, Lee KH. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler. 2012 Jan;18(1):113–115.
   PubMed Web of Science ®Google Scholar
• Kleiter I, Hellwig K, Berthele A, et al. Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol. 2012 Feb;69(2):239–245.
   PubMedGoogle Scholar
• Palace J, Leite MI, Nairne A, et al. Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Arch Neurol. 2010 Aug;67(8):1016–1017.
   PubMedGoogle Scholar
• Tahara M, Oeda T, Okada K, et al. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2020 April 01;19(4):298–306.
   PubMed Web of Science ®Google Scholar
• Cohen M, Romero G, Bas J, et al. Monitoring CD27+ memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: results from a bicentric study. J Neurol Sci. 2017 Feb 15;373:335–338.
   PubMed Web of Science ®Google Scholar
• Kim S-H, Huh S-Y, Lee SJ, et al. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol. 2013;70(9):1110–1117.
   PubMed Web of Science ®Google Scholar
• Kim S-H, Park NY, Kim KH, et al. Rituximab-induced hypogammaglobulinemia and risk of infection in neuromyelitis optica spectrum disorders: a 14-year real-life experience. Neurol Neuroimmunol Neuroinflamm. 2022;9(5):e1179.
   PubMedGoogle Scholar
• Zhang C, Zhang M, Qiu W, et al. Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial. Lancet Neurol. 2020;19(5):391–401.
   PubMed Web of Science ®Google Scholar
• Fujihara K, Bennett JL, de Seze J, et al. Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology. Neurol Neuroimmunol Neuroinflamm. 2020 Sep 3;7(5):e841.
   PubMed Web of Science ®Google Scholar
• Du C, Zeng P, Han JR, et al. Early initiation of tocilizumab treatment against moderate-to-severe myelitis in neuromyelitis optica spectrum disorder. Front Immunol. 2021;12:660230.
   PubMedGoogle Scholar
• Kharel S, Shrestha S, Ojha R, et al. Safety and efficacy of interleukin-6-receptor inhibitors in the treatment of neuromyelitis optica spectrum disorders: a meta-analysis. BMC Neurol. 2021 Nov 23;21(1):458.
   PubMedGoogle Scholar
• Ringelstein M, Ayzenberg I, Lindenblatt G, et al. Interleukin-6 receptor blockade in treatment-refractory MOG-IgG–associated disease and neuromyelitis optica spectrum disorders. Neurol Neuroimmunol Neuroinflammat. 2022;9(1):e1100.
   PubMed Web of Science ®Google Scholar
• Lotan I, Charlson RW, Ryerson LZ, et al. Effectiveness of subcutaneous tocilizumab in neuromyelitis optica spectrum disorders. Mult Scler Relat Disord. 2020;39:101920.
   PubMed Web of Science ®Google Scholar
• Thomas TC, Rollins SA, Rother RP, et al. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol. 1996 Dec;33(17–18):1389–1401.
   PubMed Web of Science ®Google Scholar
• Duan T, Smith AJ, Verkman AS. Complement-dependent bystander injury to neurons in AQP4-IgG seropositive neuromyelitis optica. J Neuroinflammation. 2018 October 22;15(1):294.
   PubMedGoogle Scholar
• Saadoun S, Waters P, Bell BA, et al. Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain. 2010;133(2):349–361.
   PubMed Web of Science ®Google Scholar
• Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in aquaporin-4–positive neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381(7):614–625.
   PubMed Web of Science ®Google Scholar
• Cree BAC, Bennett JL, Kim HJ, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet. 2019 Oct 12;394(10206):1352–1363.
   PubMed Web of Science ®Google Scholar
• Yamamura T, Kleiter I, Fujihara K, et al. Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381(22):2114–2124.
   PubMed Web of Science ®Google Scholar
• Traboulsee A, Greenberg BM, Bennett JL, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol. 2020;19(5):402–412.
   PubMed Web of Science ®Google Scholar
• Espiritu AI, Pasco PMD. Efficacy and tolerability of azathioprine for neuromyelitis optica spectrum disorder: a systematic review and meta-analysis. Mult Scler Relat Disord. 2019 Aug;33:22–32.
   PubMed Web of Science ®Google Scholar
• Songwisit S, Kosiyakul P, Jitprapaikulsan J, et al. Efficacy and safety of mycophenolate mofetil therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis. Sci Rep. 2020;10(1):16727.
   PubMedGoogle Scholar
• Sanderson J, Ansari A, Marinaki T, et al. Thiopurine methyltransferase: should it be measured before commencing thiopurine drug therapy? Ann Clin Biochem. 2004 Jul;41(Pt 4):294–302.
   PubMedGoogle Scholar
• Rual C, Biotti D, Lepine Z, et al. 2 grams versus 1 gram rituximab as maintenance schedule in multiple sclerosis, neuromyelitis optica spectrum disorders and related diseases: what B-cell repopulation data tell us. Mult Scler Relat Disord. 2023 Feb 10;71:104563.
   PubMedGoogle Scholar
• Zhao-Fleming HH, Valencia Sanchez C, Sechi E, et al. CNS demyelinating attacks requiring ventilatory support with myelin oligodendrocyte glycoprotein or aquaporin-4 antibodies. Neurology. 2021;97(13):e1351–e1358.
   PubMedGoogle Scholar
• Ramanathan S, Mohammad S, Tantsis E, et al. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. J Neurol Neurosurg. 2018;89(2):127.
   PubMed Web of Science ®Google Scholar
• Chen JJ, Flanagan EP, Bhatti MT, et al. Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder. Neurology. 2020;95(2):e111–e120.
   PubMed Web of Science ®Google Scholar
• Elsbernd PM, Hoffman WR, Carter JL, et al. Interleukin-6 inhibition with tocilizumab for relapsing MOG-IgG associated disorder (MOGAD): a case-series and review. Mult Scler Relat Disord. 2021 Feb;48:102696.
   PubMed Web of Science ®Google Scholar
• Chen JJ, Huda S, Hacohen Y, et al. Association of maintenance intravenous immunoglobulin with prevention of relapse in adult myelin oligodendrocyte glycoprotein antibody–associated disease. JAMA Neurol. 2022;79(5):518–525.
   PubMedGoogle Scholar
• Hacohen Y, Wong YY, Lechner C, et al. Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease. JAMA Neurol. 2018 Apr 1;75(4):478–487.
   PubMed Web of Science ®Google Scholar
• Sotirchos ES, Vasileiou ES, Salky R, et al. Treatment of myelin oligodendrocyte glycoprotein antibody associated disease with subcutaneous immune globulin. Mult Scler Relat Disord. 2022 Jan;57:103462.
   PubMedGoogle Scholar
• Durozard P, Rico A, Boutiere C, et al. Comparison of the response to rituximab between myelin oligodendrocyte glycoprotein and aquaporin-4 antibody diseases. Ann Neurol. 2020 Feb;87(2):256–266.
   PubMed Web of Science ®Google Scholar
• Peter -H-H, Ochs HD, Cunningham-Rundles C, et al. Targeting FcRn for immunomodulation: benefits, risks, and practical considerations. J Allergy Clin Immunol. 2020;146(3):479–491.e5.
   PubMed Web of Science ®Google Scholar
• A Study to evaluate the efficacy and safety of rozanolixizumab in adult participants with Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOG-AD) (cosMOG) [Internet]. 2021 [cited 2023 Jan 2]. Available from: https://clinicaltrials.gov/ct2/show/NCT05063162.
   Google Scholar
• Patel DD, Bussel JB. Neonatal Fc receptor in human immunity: function and role in therapeutic intervention. J Allergy Clin Immunol. 2020 September 01;146(3):467–478.
   PubMedGoogle Scholar
• A study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of satralizumab in patients with myelin oligodendrocyte glycoprotein antibody-associated disease (meteoroid) [internet]. 2022 [cited 2023 Jan 2]. Available from: https://clinicaltrials.gov/ct2/show/NCT05271409.
   Google Scholar
• Scott TF, Yandora K, Valeri A, et al. Aggressive Therapy for Neurosarcoidosis: long-term Follow-up of 48 Treated Patients. Arch Neurol. 2007;64(5):691–696.
   PubMedGoogle Scholar
• Bradshaw MJ, Pawate S, Koth LL, et al. Neurosarcoidosis: pathophysiology, diagnosis, and treatment. Neurol Neuroimmunol Neuroinflamm. 2021 Nov;8(6):e1084.
   PubMedGoogle Scholar
• Gelfand JM, Bradshaw MJ, Stern BJ, et al. Infliximab for the treatment of CNS sarcoidosis: a multi-institutional series. Neurology. 2017 Nov 14;89(20):2092–2100.
   PubMed Web of Science ®Google Scholar
• Santos E, Shaunak S, Renowden S, et al. Treatment of refractory neurosarcoidosis with Infliximab. J Neurol Neurosurg. 2010;81(3):241–246.
   PubMed Web of Science ®Google Scholar
• Hilezian F, Maarouf A, Boutiere C, et al. TNF-α inhibitors used as steroid-sparing maintenance monotherapy in parenchymal CNS sarcoidosis. J Neurol Neurosurg Psychiatry. 2021;92(8):890–896.
   PubMed Web of Science ®Google Scholar
• Kalden JR, Schulze-Koops H. Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment. Nat Rev Rheumatol. 2017 Nov 21;13(12):707–718.
   PubMed Web of Science ®Google Scholar
• Bitoun S, Bouvry D, Borie R, et al. Treatment of neurosarcoidosis: a comparative study of methotrexate and mycophenolate mofetil. Neurology. 2016 Dec 13;87(24):2517–2521.
   PubMed Web of Science ®Google Scholar
• Devine MF, Kothapalli N, Elkhooly M, et al. Paraneoplastic neurological syndromes: clinical presentations and management. Ther Adv Neurol Disord. 2021;14:175628642098532.
   Google Scholar
• Farber RS, Gross R, Zakin E, et al. Risk of venous thromboembolism in neuromyelitis optica patients hospitalized for acute relapse. Mult Scler J. 2017;23(7):988–994.
   PubMedGoogle Scholar
• Schünemann HJ, Cushman M, Burnett AE, et al. American society of hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. Blood Adv. 2018;2(22):3198–3225.
   PubMed Web of Science ®Google Scholar
• Sadowsky CL, Becker D, Bosques G, et al. Rehabilitation in transverse myelitis. Continuum (Minneap Minn). 2011 Aug;17(4):816–830.
   PubMedGoogle Scholar
• Usmani N, Bedi G, Lam BL, et al. Association between paroxysmal tonic spasms and neuromyelitis optica. Arch Neurol. 2012 Jan;69(1):121–124.
   PubMedGoogle Scholar
• Ferrell PB Jr., McLeod HL. Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics. 2008;9(10):1543–1546.
   PubMed Web of Science ®Google Scholar
• Chen P, Lin JJ, Lu CS, et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med. 2011 Mar 24;364(12):1126–1133.
   PubMed Web of Science ®Google Scholar
• Otero-Romero S, Sastre-Garriga J, Comi G, et al. Pharmacological management of spasticity in multiple sclerosis: systematic review and consensus paper. Mult Scler. 2016 Oct;22(11):1386–1396.
   PubMed Web of Science ®Google Scholar
• Fujihara K, Hattori S, Kleiter I, et al. Patient-reported burden of symptoms in neuromyelitis optica: a secondary analysis on pain and quality of life. J Neurol Sci. 2021 September 15;428:117546.
   PubMedGoogle Scholar
• Ayzenberg I, Richter D, Henke E, et al. Pain, depression, and quality of life in neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflammat. 2021;8(3):e985.
   PubMedGoogle Scholar
• Asseyer S, Henke E, Trebst C, et al. Pain, depression, and quality of life in adults with MOG-antibody-associated disease. Eur J Neurol. 2021 May;28(5):1645–1658.
   PubMedGoogle Scholar
• Mealy MA, Kozachik SL, Cook LJ, et al. Scrambler therapy improves pain in neuromyelitis optica: a randomized controlled trial. Neurology. 2020 May 5;94(18):e1900–e1907.
   PubMedGoogle Scholar
• Galati A, Brown ES, Bove R, et al. Glucocorticoids for therapeutic immunosuppression: clinical pearls for the practicing neurologist. J Neurol Sci. 2021 Nov 15;430:120004.
   PubMedGoogle Scholar
• Sechi E, Shosha E, Williams JP, et al. Aquaporin-4 and MOG autoantibody discovery in idiopathic transverse myelitis epidemiology. Neurology. 2019;93(4):e414.
   PubMedGoogle Scholar
• Cortese R, Prados Carrasco F, Tur C, et al. Differentiating multiple sclerosis from AQP4-neuromyelitis optica spectrum disorder and MOG-antibody disease with Imaging. Neurology. 2023;100(3):e308–e323.
   PubMedGoogle Scholar
• Mariano R, Messina S, Roca-Fernandez A, et al. Quantitative spinal cord MRI in MOG-antibody disease, neuromyelitis optica and multiple sclerosis. Brain. 2021 Feb 12;144(1):198–212.
   PubMedGoogle Scholar
• Zhuo Z, Zhang J, Duan Y, et al. Automated classification of intramedullary spinal cord tumors and inflammatory demyelinating lesions using deep learning. Radiol Art Int. 2022;4(6):e210292–e210292.
   PubMedGoogle Scholar
• Rice DR, Nishiyama S, Pardo S, et al. A point-of-care diagnostic test for aquaporin-4 antibody seropositive neuromyelitis optica. Mult Scler Relat Disord. 2022 April 01;60:103716.
   PubMedGoogle Scholar
• Kothur K, Wienholt L, Brilot F, et al. CSF cytokines/chemokines as biomarkers in neuroinflammatory CNS disorders: a systematic review. Cytokine. 2016 Jan;77:227–237.
   PubMed Web of Science ®Google Scholar
• Wilson R, Makuch M, Kienzler A-K, et al. Condition-dependent generation of aquaporin-4 antibodies from circulating B cells in neuromyelitis optica. Brain. 2018;141(4):1063–1074.
   PubMedGoogle Scholar